Mesenchymal Stem Cells in the Treatment of New Coronavirus Pandemic: A Novel Promising Therapeutic Approach
| Autor: | Sara Razi, Zahra Molavi, Seyed Amir Mirmotalebisohi, Zahra Niknam, Marzieh Sameni, Vahid Niazi, Amirjafar Adibi, Mohsen Yazdani, Mohammad Mehdi Ranjbar, Hakimeh Zali |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Advanced Pharmaceutical Bulletin, Vol 12, Iss 2, Pp 206-216 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2228-5881 2251-7308 |
| DOI: | 10.34172/apb.2022.023 |
| Popis: | After severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks, coronavirus disease 2019 (COVID-19) is the third coronavirus epidemic that soon turned into a pandemic. This virus causes acute respiratory syndrome in infected people. The mortality rate of SARS-CoV-2 infection will probably rise unless efficient treatments or vaccines are developed. The global funding and medical communities have started performing more than five hundred clinical examinations on a broad spectrum of repurposed drugs to acquire effective treatments. Besides, other novel treatment approaches have also recently emerged, including cellular host-directed therapies. They counteract the unwanted responses of the host immune system that led to the severe pathogenesis of SARS-CoV-2. This brief review focuses on mesenchymal stem cell (MSC) principles in treating the COVID-19. The US clinical trials database and the world health organization database for clinical trials have reported 82 clinical trials (altogether) exploring the effects of MSCs in COVID-19 treatment. MSCs also had better be tried for treating other pathogens worldwide. MSC treatment may have the potential to end the high mortality rate of COVID-19. Besides, it also limits the long-term inability of survivors. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|